Cardiovascular Health during and after Cancer Therapy.
Kathryn J RuddyShruti R PatelAlexandra S HigginsSaro H ArmenianJoerg HerrmannPublished in: Cancers (2020)
Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.
Keyphrases
- cell therapy
- cancer therapy
- epidermal growth factor receptor
- stem cells
- bone marrow
- atrial fibrillation
- drug delivery
- arterial hypertension
- healthcare
- heart failure
- endothelial cells
- squamous cell carcinoma
- emergency department
- advanced non small cell lung cancer
- left ventricular
- radiation therapy
- tyrosine kinase
- oxidative stress
- acute coronary syndrome
- papillary thyroid
- oral anticoagulants
- catheter ablation
- pluripotent stem cells
- venous thromboembolism